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Practical guide to sample size calculations:
an introduction
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Abstract
A sample size justification is a vital step when designing any trial. How-
ever, estimating the number of participants required to give a meaningful
result is not always straightforward. A number of components are required
to facilitate a suitable sample size calculation. In this paper, the general
steps are summarised for conducting sample size calculations with practical
advice and guidance on how to utilise the app SampSize.
1 Introduction
When planning a study, an essential step is the calculation of the minimum
sample size required to meet the study objectives. Estimating the number of
participants required to give a meaningful result is not always straightforward.
A study with a poorly calculated sample size not only wastes resources but also
has ethical implications. Recruiting too many participants runs the risk of more
individuals than necessary receiving an inferior treatment. Too few may not give
enough evidence to answer the original research question [1]. The motivations
for and against a sample size calculation are discussed in Table 1
This paper is the first in a series of three articles. It summarises some
important concepts required for sample size estimation. The steps needed to
carry out calculations are outlined and demonstrated using the app SampSize.
Subsequent papers demonstrate these steps for various trial objectives focussing
on trials with a Normal primary endpoint. The series provides a condensed
summary of key points and is largely adapted from the work of Julious [2].
2 SampSize
The calculations undertaken throughout the series can be carried out on the app
SampSize (developed by the University of Sheffield and epiGenesys) [3]. This
app has been developed as an aid to calculating sample sizes without the need
for familiarity with alternative statistical packages. The examples emphasise
the key components of a sample size calculation, illustrating how the app can
be utilised when a sample size is required away from a computer. Formulae and
statistical tables are also provided to aid the understanding of the components
Table 1: The motivations for carrying out sample size calculations.
A sample size justification is a requirement for any clinical
investigation. Many journals in their guidelines for authors
ask for a sample size justification. For example, the BMJ
ask for [7]
‘The sample size calculation (drawing on previous literature)
with an estimate of how many participants will be needed
for the primary outcome to be statistically, clinically and/or
politically significant.’
A sample size justification is required for an ethics submis-
sion [8] and by CONSORT [9] and is recommended as an
assessment of quality in the reporting of trials [8]-[10].
Why not do a sample size calculation?
There is rarely enough information for precise calculations.
When designing a study, a statistician will ask for any previ-
ous, similar studies to obtain information for a sample size
calculation. The information available, however, is often
either sparse or suboptimal. This is not surprising. The ra-
tionale for the trial being planned is usually to obtain good
quality information on an intervention to change prescrib-
ing or policy. If there was already good quality information,
there would be no need to conduct a trial. Thus, an in-
vestigator plans a trial to obtain good quality information
but then has poor quality information to plan the trial. Hav-
ing pilot information can assist greatly therefore in planning
[11],[12].
Even when information is available to assist with sample
size estimation, often the main constraints are availability
of patients, finance, resources and time. Even given these
final points, there should still be a sample size justification in
the protocol with a statement that the sample size is based
on feasibility disclosed.
of a sample size calculation. Details on how to obtain the app are provided in
Table 2.
3 Determining the Trial Objective
The first step in a sample size calculation is to establish the trial objective. This
motivates the type of trial to be conducted. In terms of hypothesis testing, there
are four main types of trial:
• Superiority trials,
Table 2: How to obtain the app SampSize
The SampSize app is available on the Apple App Store to
download for free and can be used on iPod Touch, iPad and
iPhones. The app is also available on the Android Market.
It requires Android version 2.3.3 and above.
For the calculations in this paper, an iPad is used.
• Non-inferiority trials,
• Equivalence trials and
• Bioequivalence trials.
We will not go into detail describing the types of trials in this paper we will
do this in the subsequent papers [4],[5].
A distinction therefore needs to be drawn to highlight differences in trials
designed to demonstrate ‘superiority’ and trials designed to demonstrate ‘equiv-
alence’ or ‘non-inferiority’. This is discussed with an emphasis on how differences
in the null and alternative hypotheses can impact on calculations.
The types of trial can often be confusing especially when formally writing
down the trial in terms of the null and alternative hypotheses. Clinical trials
are often named after their alternative hypothesis. For example, in a superior-
ity trial, the null hypothesis is that there is no difference between treatments,
and the alternative hypothesis is that there is a statistically significant differ-
ence. Informally, it is useful to consider the null hypothesis as ‘what we are
investigating’, while the alternative is ‘what we wish to show’.
A summary of these trial types and their hypotheses is given in Table 3.
In addition to trials designed to investigate an effect or lack of trials can be
undertaken to investigate possible effects for future investigation such as in
pilot or early phase trials [6]. Such trials could be designed using an estimation
approach to give a required precision around the estimates of effect. All these
trial types can be handled in SampSize (Figure 1). This series will concentrate
on superiority, non-inferiority and equivalence trials [4],[5].
It is possible a trial may have multiple objectives. In a clinical trial with
three treatment arms, a new treatment, the standard treatment and a placebo
treatment, the new drug may be compared with the placebo to test superiority
and also to the standard treatment to test for non-inferiority. In this situation,
the sample size calculation should be based on the type of trial used to achieve the
primary objective. When there are multiple primary objectives (multiplicity),
the calculations are more complex. The Committee for Proprietary Medicinal
Products (CPMP) has guidance on important points to consider when there is
multiplicity in trials [13]. The SampSize app cannot handle calculations with
multiple endpoints.
Table 3: Summary of hypotheses for different trial objectives available in the
SampSize app.
Type Description Hypotheses
Superiority Determine whether
there is evidence of a
difference in the desired
outcome between treat-
ment A and treatment
B
H0 : µA = µB vs. H1 : µA 6= µB
Non-inferiority Determine whether
there is evidence that
treatment A is not
clinically inferior to
treatment B in terms of
a clinical difference dNI
H0 : µA−µB ≤ −dNI vs. H1 : µA−µB >
1/dNI
Equivalence Determine whether
there is evidence of
no clinically mean-
ingful difference dE
between treatment A
and treatment B
H0 : µA − µB ≤ −dE or H0 : µA − µB ≥
+dE vs. H1 : −dE < µA − µB > 1/dE
Bioequivalence Determine whether
there is evidence of
no clinically mean-
ingful difference dBE
in the bioavailability
between treatment A
and treatment B
H0 : µA/µB ≤ dBE or H0 : µA/µB ≥
1/dBE vs. H1 : dBE < µA/µB < 1/dBE
Figure 1: Options available on SampSize for different trial objectives.
3.1 The Type of Trial
This series focusses on parallel group designs. In a crossover trial, each patient
receives all treatments. Usually, the order in which the participant receives the
treatment is randomised. For example, one participant may receive the active
treatment for 2 months followed by the placebo treatment for 2 months, while
another participant may receive the placebo treatment for 2 months followed by
the active treatment for 2 months.
In a parallel group trial, participants are usually randomised to one of the
treatment arms for the duration of the study. Therefore, all participants receive
one of the treatments. In a superiority trial, one group might receive an active
treatment while another group receive the placebo at the same time [14]. For
equivalence and non-inferiority trials, the alternative treatment could be the
current standard of care or an alternative active treatment.
For a parallel group trial, it is necessary to specify the allocation ratio (r).
This value determines whether equal numbers of subjects will be allocated to
each treatment arm. The most efficient design is to have equal allocation between
groups such that r = 1. However, in certain circumstances, it may be desirable
to have a larger number of participants receiving a new treatment usually of
most interest and so an allocation ratio of 2:1 might be chosen. This will result
in twice as many patients receiving the new treatment compared with the old
treatment in the trial.
4 Deciding on the Endpoint
The choice of endpoint is important in the sample size calculation. The sample
size should be calculated on the primary endpoint used to assess the primary
outcome. The endpoint can take a number of forms including the following:
• Normal,
• Binary,
• Ordinal and
• Time to event (survival).
The choice of endpoint depends on a number of factors such as the objective
of the trial. As an example, if reduction in pain is the primary objective, pain
measured on a visual analogue scale may be anticipated to take a Normal form.
A binary endpoint might be the presence or absence of pain.
The papers in this series will focus on parallel group trials where the endpoint
is anticipated to take a Normal form. However, the principles discussed can be
generalised to other data forms [2]. The app SampSize can calculate sample sizes
for both binary and Normal endpoints.
5 Error
Every trial is vulnerable to error. When estimating a sample size it is possible
to reduce the chance of making an error to a level that is deemed acceptable.
For all trial types, when testing a null hypothesis, there are two types of error
that can be made:
1. Rejecting H0 when it is actually true: type I error (α).
2. Failing to reject H0 when it is actually false: type II error (β).
The aim of the sample size calculation is to find the minimum sample size for a
fixed probability of type I error and fixed probability of a type II error.
5.1 Type I Error
A type I error (α) is the probability of rejecting the null hypothesis when it is
true. In a superiority trial, this would result in rejecting the null of no difference
between the two treatments when in fact there is one. This error is sometimes
referred to as society’s risk [6] as making this kind of mistake could result in a
treatment being made available to patients that in truth does not work or is not
efficacious.
The density plot in Figure 2 illustrates when a type I error might be made.
Even if the null hypothesis H0 is true and there is no difference between the
treatments A and B, there is still a chance that an extreme value is observed
such that the null hypothesis is rejected.
Figure 2: Density plot under the null hypothesis.
Figure 3: Density plot under the alternative hypothesis.
It is possible to reduce the chances of a type I error by reducing the level
of ‘statistical significance’ required. This results in moving the tails further
away from zero before a difference is accepted as being statistically significant.
The convention for a superiority trial is to set the significance level at a two-
sided level of 5% [15]. As will be highlighted in subsequent papers in the series,
this convention changes depending on the objective of the trial: such as for
equivalence and non-inferiority.
5.2 Type II Error and Power
A type II error (β) is the probability of failing to reject the null hypothesis when
it is false. This is often known as the investigator’s risk as if the investigator fails
to detect a treatment that works, then they will miss an opportunity to market
and benefit financially. It is desirable to make this error as small as possible.
Conventionally, this value is between 10% and 20% [14],[17].
Figure 3 illustrates when a type II error might be made. Under the alternative
hypothesis H1, there is a distribution of responses if the alternative is true,
centred on a difference d. There is still a chance a difference will be observed
that will provide insufficient evidence to reject the null hypothesis.
A type II error is usually larger than the type I error as the cost to society
of making an error of this type is lower. In a superiority trial, if we fail to reject
a null of no difference between a treatment and placebo, then the treatment will
not get used even though it is superior. If the trial was a placebo-controlled trial
and there are already many other treatments in the same class for the condition
on the market, the cost to society may not be great.
As a counter to this, if we reject the null hypothesis when it is true (type
I error), it is possible a treatment will become available to patients that is no
better than placebo. In health services research where the two treatments could
be two care pathways, then a new care pathway may be needlessly introduced.
In both these instances, introducing the new treatment will be to the detriment
of society.
In sample size calculations, it is more common to work in terms of the power
of a clinical trial. Power is one minus the probability of a type II error, thus
giving the probability of correctly rejecting the null hypothesis. Therefore, power
is usually set to be between 80% and 90%. The minimum power should be 80%.
Because of the practical nature of conducting a clinical trial, it is recom-
mended to set the power as high as possible, preferably at least 90%. When
designing a trial, it is necessary to estimate the population standard deviation
and study completion rates. These are just estimates however, and once the trial
has started, you may find them to be awry. If the standard deviation is higher
and the completion rate lower than anticipated, the sample size might need to
be increased to maintain the desired power. However, this can have logistical
impacts on the conduct of the trial: increased budgets, timeline extensions and
protocol amendments. If the study was designed with 90% power, then a deci-
sion could be made to forego a little power to maintain the same budget and
timelines. If this study was designed with 80% power, there may not be this
option as the study is already at its minimum power. A 90% powered study
is less sensitive to the assumptions in the sample size calculation than a 80%
powered study.
It is worth noting that for publicly funded trials, trials designed with 80%
power are over twice as likely not to recruit at least 80% of their target sample
size compared with those designed with 90% power; indeed, planning a trial with
80% power could be seen as a marker for a study that may fail to recruit [16]. A
study may be planned with 80% power as a priori, there is an anticipation that
the trial would struggle to recruit.
6 Effect Size (or Margin)
The effect size is probably the main factor in estimating sample size [2]. In a
superiority trial, it may be desirable to test the null hypothesis of no difference
between, say, treatment A and treatment B against an alternative hypothesis
that the two treatments differ by an amount d. This amount d is the effect size.
This is also known as a clinically important difference or the minimum value
worth detecting [17].
Determining an effect size upon which to base a sample size calculation is
often difficult. Ideally, the effect size will be based on a quantitative assessment,
but its estimation may also require a qualitative component. One approach for
Figure 4: Meta-analysis for a visual analogue scale across seven studies.
the estimation of treatment effects is to use a meta-analysis of previous results
using methods such as those proposed by Whitehead and Whitehead [18].
We will talk in greater detail on non-inferiority and equivalence margins in
the sample size papers for these calculations [5].
6.1 Worked Example
Suppose we are planning a study in an osteoarthritis population. Information
from seven trials is available, which could help design our trial. The endpoint to
be used in the planned trial is physical function measured on a visual analogue
scale (VAS).
As the different studies used different VAS measures, rather than the mean
difference (x¯A − x¯B), a scale independent standardised estimate of effect (x¯A −
x¯B)/s should be used, where s is the standard deviation. A meta-analysis can be
conducted with these standardised differences [18]. This can assist in deriving
the clinically important difference to use in the design of the proposed trial.
The forest plot in Figure 4 gives the overall standardised effect as 0.46. The
assumed standard deviation for the trial is 22mm, using this standard deviation
a standardised effect of 0.46 would equal a difference of 10mm on the VAS scale
as 0.46 = 10/22 (actually 0.46 = 10.12/22 as there is a little rounding error).
In addition, the smallest observed effect was 0.22 (equating to a difference of
4.5mm). Therefore, the sample size calculation of the proposed trial can be
based on an effect size of 10mm on the VAS.
7 Population Variance
Another component of a sample size calculation is an estimate of the population
variability. This is often estimated based on retrospective data from a collec-
tion of studies. To adjudicate on the relative quality of the variance, Julious
recommends examining the following [14]:
1. Design Is the study design ostensibly similar to the one you are designing?
Data from observational studies rather than randomised controlled trials
might have greater variability [2]. If undertaking a multi-centre trial, has
the variance been estimated from a similarly designed trial? Is the time
between treatment and the outcome of interest similar to your own study?
2. Population Consideration of the demographics of the study population is
crucial. Is the study population similar? If the trial conducted was multi-
centre, was it conducted in similar countries? Different countries may have
different types of care (e.g. different concomitant medication) and so may
have different trial populations. Was the same type of patient enrolled (the
same mix of mild, moderate and severe)? Was it conducted covering the
same seasons (relevant for conditions such as asthma)?
3. Analysis It is important to establish whether the same analysis was con-
ducted and same summary statistics used. We are often faced with little
information to inform the design of a new clinical trial; however, if we had
the information needed say from a large clinical trial we may not need
to carry out the current trial at all as we would already have the answers
we need. If there is little to no information about the variance upon which
to calculate a sample size, it might be advisable to consider an adaptive
approach and re-estimating the sample size during the trial [2].
8 Other Design Considerations
When estimating a sample size, some other factors need to be accounted for. It
may be desirable to account for potential dropouts in a study. An estimate of
this rate might be obtainable from previous research and experience
In the CACTUS pilot study [19], participants suffering from long-standing
aphasia post stroke were randomised to either a computer-based treatment or
usual care. The observed dropout rate was 5 out of 33 (15%, 95% CI: 5-32%),
translating into a completion rate of 28/33 (85%, 95% CI: 68-95%). This in-
formation was then used to inform the sample size calculation of the definitive
study by first calculating the required sample size using all of the steps discussed
here and then dividing this value by the completion rate.
Note a common error with a dropout rate of 15% is to multiply the evaluable
sample size by 1.15; however, this yields incorrect results. It is necessary to
divide the evaluable sample size by 0.85 to obtain the necessary total sample
size.
Also, it is necessary to establish the number of available participants that
meet the inclusion criteria. It is not useful to calculate a sample size of 500
patients only to then find that the patient population is actually just 250 at
the centres where you are recruiting. A consideration when recruiting for a trial
is whether the trial is recruiting from a prevalent population or a presenting
population.
In the cluster randomised controlled trial PLEASANT, a postal intervention
is sent to parents or carers of school children with asthma during the summer
holidays. This aims to reduce the number of unscheduled medical contacts in
September [20]. Although GP practices had to be recruited into the trial, in
terms of the patient population, the study had a prevalent population. It was
estimated, with reasonable precision, the number of children with asthma for a
given GP practice size.
A presenting population was used in the RATPAC clinical trial [21] where
the effectiveness of point of care marker panels was assessed in patients with sus-
pected but not proven acute myocardial infarction. In this study, the population
was patients attending the emergency department with suspected acute myocar-
dial infarction. It was important to estimate the number of people who were
likely to have this event and meet the inclusion criteria at the centres involved
in the study to establish a realistic sample size for the trial.
Many trials recruit from a combination of both presenting and prevalent
patients. For example, for trials such the CACTUS trial, the initial bolus of
recruitment was prevalent patients who meet the entry criteria followed by a
wait as new patients then presented.
Even once the number of available patients has been estimated, it is often the
case that the actual recruitment seen once the trial has begun is considerably
less than expected. Lasagna’s Law [22], Figure 5, illustrates how many clini-
cal trialists feel eligible trial patients present themselves to recruiting centres.
Lasagna states that the number of available patients drops dramatically once
the study begins and returns to the usual numbers as soon as the trial ends.
Even with good planning, recruitment can behave unexpectedly, and it is
valuable to anticipate carefully potential recruitment rates. It was discussed
earlier how studies should be planned with 90% power due to the sensitivity
of the study to study design assumptions. Recruitment rates are one major
assumption that might influence the decision to drop power if they are not as
great as expected.
A further consideration when designing a clinical trial is consideration of the
intent to treat (ITT) or per protocol (PP) data sets.
The ITT population is the patient population evaluated based on the treat-
ment regimen patients were planned to receive when they were first randomised
as opposed to the actual treatment given. As a consequence, ‘subjects allocated
to a treatment group’ are ‘followed up, assessed and analysed as members of that
group irrespective of their compliance to the planned course of treatment’ [15].
The PP population is evaluated based on the patients who complied with
the protocol for a particular treatment regimen. This may not be the treatment
they were randomised to initially [15].
Figure 5: Illustration of Lasagna’s law.
For a superiority trial, the primary data set would be that based on ITT
data set; for a non-inferiority and equivalence trial, the primary data set would
be both the PP and the ITT data sets [23].
9 Sensitivity
In the steps highlighted, a number of key components to a sample size calculation
are discussed. It is useful, however, to establish how sensitive the calculation is
to changes in each of these parameters in Table IV. Choosing 80% power rather
than 90% results in a 25% saving in the sample size; however, this is at the
expense of doubling the type II error. This also reduces flexibility once the trial
has begun, for example, if recruitment is slower than expected. Reducing the
effect size by half will also quadruple the required sample size [14]. In a non-
inferiority or equivalence trial, it will be changes in the limits chosen that affect
the sample size.
To illustrate how changing each of these parameters can affect sample size,
the formula for a superiority parallel group trial is used
nA =
(r + 1)(Z1−β + Z1−α/2)
2(σ2)
rd2
(1)
This formula is explained in detail in the following paper in the series [5].
Here, we will set the allocation ratio to r = 1. The other parameters are fixed at
α = 0.05, β = 0.1, d = 5 and σ = 10. In turn, each of the parameters is varied
over a range of values while holding the other parameters at the values given in
the preceding text. These plots are given in Figure 6.
In plots a, b and c, we can see that when the effect size, the type I error (α)
and the type II error (β) respectively are increased the sample size decreases.
However, in plot d, as the standard deviation increases, our uncertainty increases,
and thus, the sample size increases.
Table 4: Influence of changes in parameters on sample size.
Parameter increase Parameter decrease
Effect size Sample size decreases Sample size increases
Type I error Sample size decreases Sample size increases
Type II error Sample size decreases Sample size increases
Standard deviation Sample size increases Sample size decreases
10 Summary
Sample size justifications are a vital part of any clinical investigation. A number
of components are required to ‘cook up’ a suitable sample size calculation. In this
paper, the general steps are summarised for conducting sample size calculations
once all of the components are estimated.
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